Walter and Eliza Hall Institute researchers have used advanced cellular, bioinformatics and imaging technology to reveal a long-lived type of stem cell in the breast that is responsible for the growth of the mammary glands during pregnancy. The newly discovered stem cells, which respond to the ‘ovarian hormones’ progesterone and oestrogen, may also be linked to a high-risk form of breast cancer.
Category: Breast Cancer
Newly discovered breast stem cells wake up when exposed to ovarian hormones
Walter and Eliza Hall Institute researchers have used advanced cellular, bioinformatics and imaging technology to reveal a long-lived type of stem cell in the breast that is responsible for the growth of the mammary glands during pregnancy. The newly discovered stem cells, which respond to the ‘ovarian hormones’ progesterone and oestrogen, may also be linked to a high-risk form of breast cancer.
Link between human body clock and breast cancer risk discovered
Biologists in Britain have discovered a link between the human body clock and the risk of breast cancer, the University of Manchester announced Tuesday. Chinese-born Dr. Qing-Jun Meng and Professor Charles Streuli have discovered that breast tissues have 24-hour body clocks, and that several hundred genes are regulated in a daily cycle.
p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA
467 Zhongshan Road, Shahekou District, Dalian, Liaoning 116000, China. E-mail: dlzhaozw@163.com Aberrant p62 overexpression has been implicated in breast cancer development.
US cancer deaths down 25 percent since 1991
Fewer Americans are dying from the second biggest killer in the U.S.: cancer. New numbers from the American Cancer Society show from 1991 to 2014, the cancer death rate has dropped by a quarter.
Oncolytics Biotech Inc. Announces 2016 Year-End Results
“Through this process, and with the help of our expanding senior team, we thoughtfully and deliberately put in place a plan that initially contemplates combinations with chemotherapy for late-stage clinical development, but will expand to include targeted immunotherapies over the longer term as we look to leverage the role of the immune system in patient treatment. In the coming months we will specifically define our first registration pathway.